There has been some buying and selling insider activity on Natus Medical Incorporated (NASDAQ:BABY) recently. James B. Hawkins, President and CEO reported the purchase of 10,000 shares. The shares were bought on September 28th for an average price of $38.48. Hawkins now owns $17,690,218 of the stock per the Form 4 SEC filing. Robert A. Gunst, Director sold $173,050 worth of shares at an average price of $34.61 on Tue the 26th. That brings the Director’s holdings to $1,730,500 as reported to the SEC.
Yesterday Director Ken Ludlum disclosed the sale of 6,625 shares of BABY stock. The shares sold for $33.01. The Director now owns $2,651,528 of the stock according to the SEC filing.
These funds have also shifted positions in (BABY). As of quarter end Mason Street Advisors, LLC had acquired a total of 1,152 shares growing its stake by 21.6%. The value of the investment in BABY went from $256,000 to $245,000 a change of 4.3% quarter to quarter. As of the end of the quarter Royal Bank Of Canada had sold 5 shares trimming its holdings by 20.0%. The value of the investment in Natus Medical Incorporated decreased from $1,000 to $1,000 decreasing 0.0% quarter over quarter.
Ifp Advisors, Inc downsized its investment by shedding 18 shares a decrease of 4.8% from 03/31/2016 to 06/30/2016. Ifp Advisors, Inc controls 357 shares with a value of $13,000. The total value of its holdings decreased 7.1%. As of quarter end Schwab Charles Investment Management Inc had acquired 4,098 shares growing its position 3.6%. The value of the investment in (BABY) decreased from $5,407,000 to $4,408,000 a change of $999,000 for the reporting period.
On September 13 the company was rated “Outperform” according to a Raymond James report up from the previous “” rating. April 5 investment analysts at Roth Capital made no change to the stock rating of “Buy” but moved down the price target to $39.00 from $44.00.
On October 7, 2014 the stock rating was changed to a “Outperform” in a report from William Blair which is down from the previous “Market Perform” rating.
The company is so far trading up since yesterday’s close of $39.32. The stock is trading at $39.73 barely below the 50 day moving average of $40.33 and a tad above the 200 day moving average of $36.78. The 50 day moving average went down by -2.18% and the 200 day average was up $2.67.
Natus Medical Incorporated’s P/E ratio is 34.01 and the market cap is 1.28B. In the latest earnings report the EPS was $1.16 and is expected to be $1.65 for the current year with 32,437,000 shares presently outstanding. Next quarter’s EPS is expected be $0.51 and the next full year EPS is projected to be $1.75.
Traders are a little more bullish on Natus Medical Incorporated recently as inferred by the fall in short interest. The company saw a fall in short interest between August 31, 2016 and September 15, 2016 of -0.08%. Short interest decreased 71,189 over that period. The days to cover decreased to 2.3 and the short interest percentage is 0.02% as of September 15.